07
Mar

In contrast to NewLink Genetics, Northwest Biotherapeutics’ interim analysis was a boon to the company’s investors, as word that its Phase III trial of a personalized cancer vaccine was going according to plan sent its shares up as much as 10%.

…read more

Source: Northwest Bio jumps as Phase III trial keeps on rolling

    

0 No comments